Phathom Pharmaceuticals to Present at Two Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 01, 2026 /CourierPR/ -- Phathom Pharmaceuticals, Inc., a biopharmaceutical company dedicated to developing and commercializing novel treatments for gastrointestinal diseases, will participate in two upcoming investor conferences in September 2026.

On September 9, the company's management will present at the 2026 Cantor Global Healthcare Conference in New York City. The event will feature a fireside chat starting at 10:55 am Eastern Daylight Time (EDT). Management will also engage in one-on-one meetings throughout the conference.

Following this, Phathom will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15. The company’s representatives will deliver a fireside chat at 3:30 pm EDT and participate in one-on-one meetings.

The recordings will be available for 90 days after the conclusion of each event.

Phathom Pharmaceuticals has secured exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada. The company markets vonoprazan in the U.S. under the brand name VOQUEZNA® for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults, the healing and maintenance of healing of erosive GERD in adults, and relief of associated heartburn. It is also part of VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK® for the treatment of H. pylori infection in adults.